Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q3 FY24 Earnings Presentation
13 slides from Gland Pharma's earnings presentation, Feb 14, 2024
Slide 1: Gland Pharma Limited Financial Results Q3 FY24
GLAND PHARMA LIMITED Gland Pharma Limited Financial Results Q3’FY24 14th February 2024 Cemcitibii lajectiM ■
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Group Financial Highlights (1/4)
Group Financial Highlights (1/4) Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (INR Mn) (INR Mn / %) 25,536 41,273 85% 62% 28,396 15,190 8,519 9,459 53% 13,734 15,452 9,383 5,112 61% 62% 54% Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 EBITDA (
Slide 4: Gland Financial Highlights (Ex-Cenexi) (2/4)
Gland Financial Highlights (Ex-Cenexi) (2/4); Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn / %) (INR Mn) 15% 6% 9,836 8,563 28,396 30,032 29% 33% 30% 3,473 3,727 9,383 10,146 11,013 2,896 34% 34% 31% Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 Q3 FY23 Q2 FY24 Q3 FY24 9M FY23 9M FY24 PB
Slide 5: Group Financial Highlights (3/4)
Group Financial Highlights (3/4) Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 79,587 85,736 37,707 37,669 24,795 20,704 Mar'23 Dec'23 Mar'23 Dec'23 Total Cash Net Cash ■ Net Working Capital (3) Capital Expenditure (INR Mn) (INR Mn) 24,010 22,805 2,467 1,253 Mar'23 Dec'23 9M
Slide 6: Group Financial Highlights (4/4)
Group Financial Highlights (4/4) Asset Turnover Ratio (1)(2) ROCE (3) / RONW (4) (%) 2.4 2.2 12% 11% 1.6 12% 9% 11% 9% 0.5 0.5 0.5 Total asset turnover Fixed asset turnover 9M FY23 FY23 9M FY24 9M FY23 FY23 9M FY24 RoCE RoNW Cash Flow from Operations Cash Conversion Cycle (CCC) (5)(6) (INR Mn) (# of
Slide 7: P&L Highlights
P&L Highlights Group P&L (INR Mn) Particulars Q3 FY24 Q3 FY23 YoY 9M FY24 9M FY23 YoY Q2 FY24 QoQ Revenue from operations 15,452 9,383 65% 41,273 28,396 45% 13,734 13% Other Income 374 615 -39% 1,281 2,015 -36% 532 -30% Total Income 15,826 9,998 58% 42,554 30,411 40% 14,266 11% Gross Margin(1) 9,459
Slide 8: Q3 FY24 key highlights
Q3 FY24 key highlights Gland (Ex-Cenexi) • Quarter-over-quarter growth propelled by consistent performance, increased volumes shipped in a stable pricing environment, and the introduction of new products. • Manufacturing sites remain operational with efficiency, and the company is committed to deliv
Slide 9: US Market
US Market Group Revenue Contribution ▪ Revenue: Launched 9 molecules in the market, including 9M FY24: Rs. 21,591 Mn Q3 FY24: Rs. 8,216 Mn YoY Change: 14% YoY Change: 41% Octreotide Acetate, Ketamine, Zinc Sulfate and Levothyroxine Sodium. Increase in volume for some of the key products, such Q3 Q3
Slide 10: Europe, Other Core Markets (Canada, Australia and New Zealand)
Europe, Other Core Markets (Canada, Australia and New Zealand) Europe Other Core Markets (Canada, Australia and New Zealand) Group Revenue Contribution Group Revenue Contribution 9M FY24: Rs. 7,963 Mn Q3 FY24: Rs. 3,251 Mn 9M FY24: Rs. 998 Mn Q3 FY24: Rs. 382 Mn YoY Change: 415% YoY Change: 435% YoY
Slide 11: Rest of the World Markets
Rest of the World Markets Group Revenue Contribution Rest of the World Markets ▪ The Rest of the World markets contributed 18% of our 9M FY24: Rs. 8,437 Mn Q3 FY24: Rs. 2,842 Mn YoY Change: 63% YoY Change: 46% revenue in Q3 FY24, compared to 21% in Q3 FY23. 21% 18% ▪ These markets reported a 7% QoQ
Slide 12: India (Domestic Market)
India (Domestic Market) Group Revenue Contribution India - Domestic Market (Ex-Cenexi) 9M FY24: Rs. 2,283 Mn Q3 FY24: Rs. 761 Mn ▪ The India market contributed 5% to our revenue in Q3 YoY Change: 11% YoY Change: -7% 9% 5% FY24 and experienced a 7% decrease compared to the corresponding period in the
Slide 13: GLAND
GLAND Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District